



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI   
[\[Sign In\]](#) [\[Register\]](#)

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)

Search  for

[Limits](#) [Preview/Index](#) **[History](#)** [Clipboard](#) [Details](#)

Query #13 deleted

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

[About Entrez](#)  
[NCBI Toolbar](#)

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)  
[Help | FAQ](#)  
[Tutorials](#)  
[New/Noteworthy](#)  
[E-Utilities](#)

[PubMed Services](#)  
[Journals Database](#)  
[MeSH Database](#)  
[Single Citation Matcher](#)  
[Batch Citation Matcher](#)  
[Clinical Queries](#)  
[Special Queries](#)  
[LinkOut](#)  
[My NCBI](#)

[Related Resources](#)  
[Order Documents](#)  
[NLM Mobile](#)  
[NLM Catalog](#)  
[NLM Gateway](#)  
[TOXNET](#)  
[Consumer Health](#)  
[Clinical Alerts](#)  
[ClinicalTrials.gov](#)  
[PubMed Central](#)

#### Search

#### Most Recent Queries

Time Result

<a href="#">#20</a>	Search "Bile Acids and Salts"[MeSH] AND "Immunoprecipitation"[MeSH] AND ("Lipoproteins, HDL"[MeSH] AND "Lipoproteins, LDL"[MeSH])	14:06:29	<a href="#">2</a>
<a href="#">#11</a>	Search "Immunoprecipitation"[MeSH] AND ("Lipoproteins, HDL"[MeSH] AND "Lipoproteins, LDL"[MeSH])	14:05:56	<a href="#">142</a>
<a href="#">#10</a>	Search "Immunoprecipitation"[MeSH] AND ("Lipoproteins, HDL"[MeSH] OR "Lipoproteins, LDL"[MeSH])	13:47:55	<a href="#">630</a>

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jan 9 2006 04:55:34

L1 40 S SUGIUCHI  
 L2 17 S L1 AND (CHOLESTEROL OR LIPOPROTEIN)  
 L3 16 DUP REM L2 (1 DUPLICATE REMOVED)  
 L4 9984 S (CYCLODEXTRAN OR DEXTRAN SULFATE) AND (CHOLESTEROL OR LIPOPRO  
 L5 1280 S L4 AND (POLYOXYETHYLENE OR POLYOXYPROPYLENE)  
 L6 883 S L5 AND (OXIDASE OR ESTERASE OR DEHYDROGENASE)  
 L7 843 S L6 AND (HOMOGENEOUS OR SIMULTANEOUS? OR CONTINUOUS OR SINGL  
 L8 820 DUP REM L6 (63 DUPLICATES REMOVED)  
 L9 764 S L8 AND FRACTION?  
 L10 10 S L9 AND (LIPOPROTEIN OR LDL OR HDL OR LDL-C OR HDL-C OR APOL  
 L11 19 S L5 AND (LIPOPROTEIN OR LDL OR HDL OR LDL-C OR HDL-C OR APOL  
 L12 9 S L11 NOT L10  
 L13 2 DUP REM L12 (7 DUPLICATES REMOVED)

=> file bioscience  
 FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED  
 COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.48

=> s sugiuchi  
 33 FILES SEARCHED...  
 66 FILES SEARCHED...  
 L1 40 SUGIUCHI

=> s l1 and (cholesterol or lipoprotein)  
 25 FILES SEARCHED...  
 L2 17 L1 AND (CHOLESTEROL OR LIPOPROTEIN)

=> dup rem l2  
 DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,  
 FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN,  
 PHAR, PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.  
 ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
 PROCESSING COMPLETED FOR L2  
 L3 16 DUP REM L2 (1 DUPLICATE REMOVED)

=> d l3 1-16 ibib abs

L3 ANSWER 1 OF 16 USPATFULL on STN  
 ACCESSION NUMBER: 2005:255008 USPATFULL  
 TITLE: Assay system and method for direct measurement of LDL  
**cholesterol**  
 INVENTOR(S): Shindelman, Jeffrey E., Castro Valley, CA, UNITED  
 STATES  
 Worthy, Thomas E., Walnut Creek, CA, UNITED STATES  
 Jones, Ronald M., Mountain View, CA, UNITED STATES  
 Withers, George E. III, Livermore, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005221502	A1	20051006
APPLICATION INFO.:	US 2005-96761	A1	20050331 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-559382P	20040402 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PERKINS COIE LLP, P.O. BOX 2168, MENLO PARK, CA, 94026, US	
NUMBER OF CLAIMS:	19	

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 3 Drawing Page(s)  
LINE COUNT: 875  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay device and method for measuring the concentration of LDL-associated **cholesterol** in a blood-fluid sample are described. The method employs selective precipitation of VLDL and chylomicrons and immunoseparation of HDL from a blood fluid sample. The assay device allows the assay to be performed entirely in a flow strip format.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 16 USPATFULL on STN  
ACCESSION NUMBER: 2005:196305 USPATFULL  
TITLE: Reagent combination and method for direct test strip measurement of **cholesterol** from low density lipoproteins at ambient temperatures  
INVENTOR(S): Lawrence, Gregory M., Indianapolis, IN, UNITED STATES  
Pasqua, John, Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005170447	A1	20050804
APPLICATION INFO.:	US 2004-962272	A1	20041011 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-541681P	20040203 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAGINOT, MOORE & BECK, BANK ONE CENTER/TOWER, 1111 MONUMENT CIRCLE, INDIANAPOLIS, IN, 46204, US	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	863	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Cholesterol** from Low Density Lipoproteins (LDL-C) is measured directly with a test strip at room temperature using a reagent that takes advantage of the varying surface charge density on LDLs and non-LDLs to selectively make LDL-C available for testing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 16 USPATFULL on STN  
ACCESSION NUMBER: 2005:171807 USPATFULL  
TITLE: Compositions and methods for increasing HDL and HDL-2b levels  
INVENTOR(S): Tawakol, Raif, Merced, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005148556	A1	20050707
APPLICATION INFO.:	US 2004-977508	A1	20041029 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-515891P	20031029 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	106	
EXEMPLARY CLAIM:	1	

LINE COUNT: 2033

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for reducing flushing in a patient. In addition, compositions and methods are provided for increasing HDL and/or HDL-2b levels in a patient. In some embodiments, the compositions include an adipocyte G-protein antagonist, a PPAR- $\alpha$  agonist, and a PPAR- $\gamma$  agonist in amounts effective in to provide a synergistic therapeutic HDL increasing effect, and/or a synergistic therapeutic HDL-2b increasing effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2005:87366 USPATFULL

TITLE: Uae of lipase for high-density **lipoprotein cholesterol** detection

INVENTOR(S): DiMagno, Theodore John, Penfield, NY, UNITED STATES  
Arter, Thomas Charles, Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005074828	A1	20050407
APPLICATION INFO.:	US 2004-890613	A1	20040714 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-487914P	20030717 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	325	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a dry analytical element useful for the determination and quantification of high-density **lipoprotein cholesterol** (HDL) that uses yeast lipase from *Candida rugosa*, a lipase enzyme source that has **cholesterol** esterase activity, which preferentially reacts with the **cholesterol** esters of HDL over **cholesterol** esters of other lipoproteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2005:75820 USPATFULL

TITLE: Methods to increase plasma HDL **cholesterol** levels and improve HDL functionality with probucol monoesters

INVENTOR(S): Sikorski, James A., Alpharetta, GA, UNITED STATES  
Saxena, Uday, Atlanta, GA, UNITED STATES  
Luchoomun, JayRaz, Lilburn, GA, UNITED STATES  
Sundell, Cynthia L., Atlanta, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005065121	A1	20050324
APPLICATION INFO.:	US 2004-977752	A1	20041029 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-122516, filed on 11 Apr 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-283376P	20010411 (60)

US 2001-345025P 20011109 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: KING & SPALDING LLP, 191 PEACHTREE STREET, N.E.,  
ATLANTA, GA, 30303-1763  
NUMBER OF CLAIMS: 22  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 7 Drawing Page(s)  
LINE COUNT: 3559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been discovered that certain selected probucol monoesters, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL **cholesterol**. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 16 USPATFULL on STN  
ACCESSION NUMBER: 2005:43774 USPATFULL  
TITLE: One-step assay for high-density **lipoprotein cholesterol**  
INVENTOR(S): DiMagno, Theodore John, Penfield, NY, UNITED STATES  
Arter, Thomas Charles, Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005037504	A1	20050217
APPLICATION INFO.:	US 2004-890588	A1	20040714 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-488027P	20030717 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	548	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a method for quantifying **cholesterol** in high-density lipoproteins in a single step assay using a dry slide. The method for quantifying **cholesterol** in high-density **lipoprotein** comprises a first step of adding a sample onto a multi-layered dry slide wherein at least one of the layers contains phosphotungstic acid and another contains a high-density **lipoprotein** selective surfactant. The phosphotungstic acid precipitates non-high-density lipoproteins while the high-density **lipoprotein** selective surfactant only solubilizes high-density lipoproteins and does not solubilize non-HDL precipitated complexes. The **cholesterol** esterase then reacts with the solubilized HDL **cholesterol** esters to form **cholesterol**. Finally the **cholesterol** in the high-density **lipoprotein** is detected and quantified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 16 USPATFULL on STN  
ACCESSION NUMBER: 2005:37463 USPATFULL  
TITLE: Dry analytical element for high-density **lipoprotein cholesterol** quantification

INVENTOR(S): DiMagno, Theodore John, Penfield, NY, UNITED STATES  
Arter, Thomas Charles, Rochester, NY, UNITED STATES  
Chambers, Deborah Lynn, Hilton, NY, UNITED STATES  
Silva, David Paul, JR., Rochester, NY, UNITED STATES  
Vavra, Karen J., Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005032141	A1	20050210
APPLICATION INFO.:	US 2004-890610	A1	20040714 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-488101P	20030717 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	711	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A dry analytical element is disclosed which can be used for the quantification of high-density **lipoprotein cholesterol** (HDL). The element comprises a support having one or more reagent layers containing a first enzyme, a **cholesterol** ester hydrolase, to hydrolyze **cholesterol** esters, a second enzyme, **cholesterol** oxidase, to release hydrogen peroxide from **cholesterol**, and a third enzyme, horseradish peroxidase, to oxidize a leuco dye that is read at 670 nm. The element also contains phosphotungstic acid, a non-high-density **lipoprotein** precipitant, and a high-density **lipoprotein** selective surfactant, which together confer HDL selectivity on the assay. Also disclosed are polymers that improve assay precision and eliminate interference from hemolyzed patient samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 16 USPTFULL on STN

ACCESSION NUMBER: 2004:335785 USPTFULL  
TITLE: Compounds and methods to increase plasma HDL  
**cholesterol** levels and improve HDL  
functionality

INVENTOR(S): Sikorski, James A., Alpharetta, GA, UNITED STATES  
Luchoomun, Jayraz, Lilburn, GA, UNITED STATES  
Meng, Charles Q., Alpharetta, GA, UNITED STATES  
Saxena, Uday, Atlanta, GA, UNITED STATES

PATENT ASSIGNEE(S): Atherogenics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004266879	A1	20041230
APPLICATION INFO.:	US 2004-886927	A1	20040708 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-833407, filed on 11 Apr 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-196201P	20000411 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sherry M. Knowles, KING & SPALDING LLP, 45th Floor, 191 Peachtree Street, N.E., Atlanta, GA, 30303	
NUMBER OF CLAIMS:	68	

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Page(s)  
LINE COUNT: 3248  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL **cholesterol**. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 16 USPATFULL on STN  
ACCESSION NUMBER: 2004:314637 USPATFULL  
TITLE: Method for the simultaneous and direct determination of serum **cholesterol** in high an low density lipoproteins using infrared spectroscopy  
INVENTOR(S): Liu, Kan-Zhi, Manitoba, CANADA  
Shaw, Anthony, Manitoba, CANADA  
Mantsch, Henry H., Manitoba, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004248309	A1	20041209
APPLICATION INFO.:	US 2004-485413	A1	20040802 (10)
	WO 2002-CA1377		20020911

	NUMBER	DATE
PRIORITY INFORMATION:	CA 2001-2357338	20010912
	US 2001-60327766	20011010
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Ade & Company, 1700 360 Main Street, Winnipeg Manitoba, R3C 3Z3	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	688	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB A method of simultaneously determining the concentrations of cardiovascular risk markers selected from the group consisting of High Density **Lipoprotein cholesterol** (HDL-C), Low Density **Lipoprotein cholesterol** (LDL-C), total **cholesterol**, triglycerides and oxidized LDL using infra-red and/or near infrared light is described

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 16 USPATFULL on STN  
ACCESSION NUMBER: 2004:165343 USPATFULL  
TITLE: Test strip and method for determining LDL **cholesterol** concentration from whole blood  
INVENTOR(S): Shull, Bruce, Indianapolis, IN, UNITED STATES  
Zeng, Hyeon-Sook Lee, Indianapolis, IN, UNITED STATES  
Anaokar, Sunil, Indianapolis, IL, UNITED STATES  
Antonopoulos, Gena Lynn, Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126830	A1	20040701
APPLICATION INFO.:	US 2003-663555	A1	20030916 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2002-411209P	20020916 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAGINOT, ADDISON & BOWMAN, BANK ONE CENTER/TOWER, 1111 MONUMENT CIRCLE, SUITE 3000, INDIANAPOLIS, IN, 46204	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	871	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A dry phase test strip (20) and method are provided for determining the concentration of LDL in whole blood or plasma. The inventive test strip (20) includes one stack (92) or panel that measures concentration of total **cholesterol** and another stack (94) or panel that measures concentration of the sum total of HDL, VLDL and chylomicrons ("non-LDLs"). The difference between the values just noted is equal to the concentration of LDL **cholesterol**. Dry phase test strips (20) of the present invention function at room temperature and all test results are produced from pseudo-endpoint reflectance measurements such that the test method need not be timed. Also disclosed is the capability for an improved lipid panel that provides concentration in a blood sample of HDL, total **cholesterol** and LDL **cholesterol** without relying upon the Friedewald equation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 16 USPATFULL on STN  
 ACCESSION NUMBER: 2003:93606 USPATFULL  
 TITLE: Methods to increase plasma HDL **cholesterol** levels and improve HDL functionality with probucol monoesters  
 INVENTOR(S): Luchoomun, JayRaz, Lilburn, GA, UNITED STATES  
 Sundell, Cynthia L., Atlanta, GA, UNITED STATES  
 Saxena, Uday, Atlanta, GA, UNITED STATES  
 Sikorski, James A., Alpharetta, GA, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2003064967	A1	20030403
APPLICATION INFO.:	US 2002-122516	A1	20020411 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-283376P	20010411 (60)
	US 2001-345025P	20011109 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	3566	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been discovered that certain selected probucol monoesters, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL **cholesterol**. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L3 ANSWER 12 OF 16 USPATFULL on STN DUPLICATE 1  
 ACCESSION NUMBER: 2002:27516 USPATFULL  
 TITLE: Compounds and methods to increase plasma HDL  
**cholesterol** levels and improve HDL  
 functionality  
 INVENTOR(S): Luchoomun, Jayraz, Lilburn, GA, UNITED STATES  
 Meng, Charles Q., Alpharetta, GA, UNITED STATES  
 Saxena, Uday, Atlanta, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002016364	A1	20020207
	US 6881860	B2	20050419
APPLICATION INFO.:	US 2001-833407	A1	20010411 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-196201P	20000411 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763	
NUMBER OF CLAIMS:	68	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	3251	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL **cholesterol**. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 16 ANABSTR COPYRIGHT 2006 RSC on STN

AB The analytical and clinical performance of two low-density lipoprotein **cholesterol** (LDL-C) assays (LDL-CRD, Roche Diagnostics and LDL-CGZ, Genzyme) were evaluated simultaneously as well as those calculated by the Friedewald calculation (LDL-CFried) (cf., Friedewald et al.), Clin. Chemical, 1972, 18, 499). LDL-CRD utilizes the fact that at a neutral pH value (7.0) in the presence of MgCl<sub>2</sub>, sulfated  $\alpha$ -cyclodextrin and dextran sulfate, the enzymatic reaction for **cholesterol** in very low-density lipoprotein (VLDL) is markedly reduced (reagent 1). The non ionic detergent in reagent 2, selectively solubilizes LDL-C, enables measured of LDL-C by a conventional enzymatic reaction (cf., Sugiuchi et al., Clin. Chemical, 1998, 44, 522). The assay was calibrated and performed according to the manufacturer's recommendation. In the LDL-CGZ method (Genzyme, Cambridge, MA, USA), reagent 1 contains a detergent which solubilizes all non-LDL lipoproteins. The enzymes **cholesterol** esterase and **cholesterol** oxidase react with the non-LDL **cholesterol**. In the second step another detergent solubilizes the LDL-C so that it can be easily measured with a conventional enzymatic reaction (cf., Rifai et al., Clin. Chemical, 1998, 44, 1242). As before, the assay was performed according to the manufacturer's recommendations. Results (tabulated) showed that in order to classify someone correctly into the recommended National **Cholesterol** Education Program cut points, the total error requirement ( $\leq 12\%$ ), was met by the LDL-CGZ assay at all clinical decision cut-points, whereas the LDL-CND assay only met the requirement at concentrations of 4.92 mmol/l. The LDL-Cfried failed to meet the total error requirement, because the compounded imprecision of the three independent tests required for this calculation was high. At the medical decision cut-point range, LDL-CRD, LDL-CGZ and LDL-CFried assays

showed positive predictive values of 89-100, 85-100 and 83-99%, respectively, and negative predictive values of 52-98, 77-98 and 68-98%, respectively.

L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:608162 CAPLUS

DOCUMENT NUMBER: 127:289981

TITLE: Multicenter evaluation of a homogeneous assay for HDL-**cholesterol** without sample pretreatment

AUTHOR(S): Nauck, Matthias; Marz, Winfried; Jarausch, Jochen; Cobbaert, Christa; Sagers, Anja; Bernard, Dirk; Delanghe, Joris; Honauer, Gunter; Lehmann, Paul; Oestrich, Evelyn; Von Eckardstein, Arnold; Walch, Stephan; Wieland, Heinrich; Assmann, Gerd

CORPORATE SOURCE: University of Freiburg, Freiburg, Germany

SOURCE: Clinical Chemistry (Washington, D. C.) (1997), 43(9), 1622-1629

CODEN: CLCHAU; ISSN: 0009-9147

PUBLISHER: American Association for Clinical Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We evaluated, in 6 European labs., a new homogeneous assay that uses PEG-modified enzymes and  $\alpha$ -cyclodextrin sulfate to selectively determine HDL-**cholesterol** (HDL-C) in serum (**Sugiuchi**, H. et al., 1995). The assay includes two reagents and is applicable to most automated analyzers, which allows full automation. The total CVs of the new method ranged between 1.3% and 6.7%. Thereby determined HDL-C values were in good agreement with those obtained by precipitation with phosphotungstic acid/MgCl<sub>2</sub> or by a combination of ultracentrifugation and precipitation

( $0.956 < r < 0.994$ ). The assay was linear up to at least 1500 mg/L HDL-C. Hb did not interfere, whereas icteric samples with bilirubin >100 mg/L showed discrepancies between the homogeneous and the precipitation assay. Lipemia up

to

total triglyceride concns. of 8000 mg/L did not interfere with the homogeneous HDL-C assay. The homogeneous HDL-C assay was easy to handle and produced similar results in all labs. participating in this study. This method will significantly facilitate the screening of individuals at increased risk for cardiovascular disease.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 16 ANABSTR COPYRIGHT 2006 RSC on STN

AB The method of **Sugiuchi** et al. (Ibid., 1995 41, 717) for determination of high-density-lipoprotein (HDL)-**cholesterol** in serum by direct measurement with PEG-modified **cholesterol** esterase and oxidase and sulfated  $\alpha$ -cyclodextrin was evaluated. Results correlated well ( $r = 0.978$ ) with those by a precipitation method but the latter method did not completely determine HDL **cholesterol**, while the direct method discriminated well between serum HDL and low-density-lipoprotein **cholesterol**.

L3 ANSWER 16 OF 16 JICST-EPlus COPYRIGHT 2006 JST on STN

ACCESSION NUMBER: 960619585 JICST-EPlus

TITLE: Evaluation of a Direct Method for Determining High Density **Lipoprotein-Cholesterol**.

AUTHOR: SHIGI KAZUYUKI; ICHIKAWA MASAYUKI; SUGIYAMA NORIKO; SHIRAKATA TAKAHARU

CORPORATE SOURCE: Okayama Saiseikai Gen. Hosp.

SOURCE: Okayama Saiseikai Sogo Byoin Zasshi (Journal of Okayama Saiseikai General Hospital), (1995) vol. 27, pp. 106-112. Journal Code: Y0151A (Fig. 8, Ref. 12)

ISSN: 0475-008X

PUB. COUNTRY: Japan

DOCUMENT TYPE: Journal; Article  
LANGUAGE: Japanese  
STATUS: New

AB Serum high density **lipoprotein-cholesterol** (HDL-C) levels are used as an indicator of risk for coronary heart disease because the serum HDL-C level shows a strong inverse relationship with the risk of developing the disease. The method for determining HDL-C which we have previously used necessitates a cumbersome manual precipitation procedure for removing lipoproteins other than HDL prior **cholesterol** determination. We evaluated a direct HDL-C determining method (Kyouwa Medekusu Co.) with the Hitachi 7250 automated analyzer. This method was developed by **Sugiuchi** et al. (Clin Chem, 41: 717, 1995). In this method polyethylene glycol-modified **cholesterol** esterase and **cholesterol** oxidase, and A-cyclodextrin sulfate are utilized. These enzymes react more actively with HDL than with other lipoproteins, and A-cyclodextrin sulfate inhibits the catalytic activity of the enzymes on LDL, VLDL, and chylomicrons. Within-run precision and between-day precision were acceptable. Our results showed a linearity up to 120mg/dl. Conjugated bilirubin and Intralipos (Midori Jyujii Co.) gave negative errors. Hemoglobin and free bilirubin did not affect the result. Within the range from 40 to 120mg/dl, the results obtained by this method correlated well with those by our current method which is based on the pretreatment with a precipitating reagent composed of dextran sulfate and magnesium salt, giving a regression equation  $y=1.022x-3.46$  ( $r=0.9652$ ). But in specimens with high HDL, this method gave significantly higher results than did the precipitating method. We conclude that this is a reliable fully automated assay for determining serum HDL-**cholesterol**. (author abst.)

```
=> s (cyclodextran or dextran sulfate) and (cholesterol or lipoprotein)
    27 FILES SEARCHED...
    45 FILES SEARCHED...
L4      9984 (CYCLODEXTRAN OR DEXTRAN SULFATE) AND (CHOLESTEROL OR LIPOPROTEI
        N)

=> s L4 and (polyoxyethylene or polyoxypropylene)
    43 FILES SEARCHED...
L5      1280 L4 AND (POLYOXYETHYLENE OR POLYOXYPROPYLENE)

=> s L5 and (oxidase or esterase or dehydrogenase)
    33 FILES SEARCHED...
L6      883 L5 AND (OXIDASE OR ESTERASE OR DEHYDROGENASE)

=> s L6 and (homogeneous or simultaneous? or continuous or single sample)
    21 FILES SEARCHED...
    45 FILES SEARCHED...
    66 FILES SEARCHED...
L7      843 L6 AND (HOMOGENEOUS OR SIMULTANEOUS? OR CONTINUOUS OR SINGLE
        SAMPLE)

=> dup rem L6
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN,
PHAR, PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L6
L8      820 DUP REM L6 (63 DUPLICATES REMOVED)

=> s L8 and fraction?
    17 FILES SEARCHED...
    34 FILES SEARCHED...
    61 FILES SEARCHED...
L9      764 L8 AND FRACTION?
```

=> s 19 and (lipoprotein or ldl or hdl or ldl-c or hdl-c or apolipoprotein or apo-a or apo-b) (a) (fraction)

11 FILES SEARCHED...  
16 FILES SEARCHED...  
21 FILES SEARCHED...  
28 FILES SEARCHED...  
45 FILES SEARCHED...  
54 FILES SEARCHED...  
61 FILES SEARCHED...  
66 FILES SEARCHED...

L10 10 L9 AND (LIPOPROTEIN OR LDL OR HDL OR LDL-C OR HDL-C OR APOLIPO  
PROTEIN OR APO-A OR APO-B) (A) (FRACTION)

=> d 110 1-10 ibib abs

L10 ANSWER 1 OF 10 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1998:175699 BIOSIS

DOCUMENT NUMBER: PREV199800175699

TITLE: Homogeneous assay for measuring low-density

**lipoprotein cholesterol** in serum with  
triblock copolymer and alpha-cyclodextrin sulfate.

AUTHOR(S): Sugiuchi, Hiroyuki [Reprint author]; Irie, Tetsumi; Uji,  
Yoshinori; Ueno, Tomohiro; Chaen, Toshiko; Uekama, Kaneto;  
Okabe, Hiroaki

CORPORATE SOURCE: Dep. Cent. Lab., Kumamoto Univ. Hosp., 1-1-1, Honjo,  
Kumamoto 860, Japan

SOURCE: Clinical Chemistry, (March, 1998) Vol. 44, No. 3, pp.  
522-531. print.  
CODEN: CLCHAU. ISSN: 0009-9147.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 20 Apr 1998

Last Updated on STN: 12 Aug 1998

AB We have developed a fully automated method for measuring LDL-  
**cholesterol** (LDL-C) in human serum without the need for prior  
separation, using a nonionic surfactant, **polyoxyethylene-**  
**polyoxypropylene** block copolyether (POE-POP), and a sodium salt of  
sulfated cyclic maltohexaose, alpha-cyclodextrin sulfate. Of the  
surfactants tested, POE-POP with a higher molecular mass of the POP block  
and a greater hydrophobicity reduced the reactivity of **cholesterol**  
in **lipoprotein fractions**; the reactivity in descending  
order was LDL mchgt VLDL > chylomicron apprxeq HDL. Gel filtration  
chromatographic studies revealed that POE-POP removed lipids selectively  
from the **LDL fraction** and allowed them to participate  
in the **cholesterol esterase-cholesterol**  
**oxidase** coupling reaction system. By contrast, alpha-cyclodextrin  
sulfate reduced the reactivity of **cholesterol**, especially in  
chylomicrons and VLDL. A combination of POE-POP with alpha-cyclodextrin  
sulfate provided the required selectivity for the determination of LDL-C  
in serum in the presence of magnesium ions and a small amount of  
**dextran sulfate** without precipitating  
**lipoprotein** aggregates. There was a good correlation between the  
results of LDL-C assayed by the proposed method and the  
beta-quantification reference method involving 161 sera with triglyceride  
concentrations ranging from 0.3 to 22.6 mmol/L.

L10 ANSWER 2 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2005:292990 USPATFULL

TITLE: Method of selectively measuring triglycerides

INVENTOR(S): Okada, Masahiko, Niigata-shi, JAPAN

Saito, Tomohiro, Sagamihara-shi, JAPAN

Yoshimura, Hajime, Sagamihara-shi, JAPAN

PATENT ASSIGNEE(S): SHINO-TEST CORPORATION, Tokyo, JAPAN (non-U.S.  
corporation)

Masahiko OKADA, Niigata, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005255536	A1	20051117	
APPLICATION INFO.:	US 2003-516291	A1	20030604	(10)
	WO 2003-JP7066		20030604	
			20041208	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2003-2002168738	20020610
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2394	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a reagent for selective measurement of triglycerides contained in very low density **lipoprotein** and intermediate density **lipoprotein** or in very low density **lipoprotein** in a test sample, including a first reagent that contains a first selective reaction promoter, which is an ether or ester compound of a polyoxyalkylene capable of reacting **lipoprotein** lipase selectively with triglycerides contained in low density **lipoprotein** and high density **lipoprotein**; **lipoprotein** lipase; enzymes which catalyze a series of reactions leading to the generation of hydrogen peroxide or a reduced coenzyme from glycerol; and an enzyme which catalyzes a reaction leading to the conversion of hydrogen peroxide or a reduced coenzyme into another substance, and a second reagent that contains a second selective reaction promoter, which is capable of reacting **lipoprotein** lipase selectively with triglycerides contained in very low density **lipoprotein**, intermediate density **lipoprotein**, low density **lipoprotein** and high density **lipoprotein** and to a method for selective measurement of triglycerides contained in very low density **lipoprotein** and intermediate density **lipoprotein** or in very low density **lipoprotein** in a test sample which uses the above reagent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2004:235513 USPATFULL

TITLE: Methods for **fractional** quatification of **cholesterol** in lipoproteins and quantification reagents

INVENTOR(S): Sugiuchi, Hiroyuki, Kumamoto, JAPAN

PATENT ASSIGNEE(S): Kyowa Medex Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6794157	B1	20040921	
	WO 2000017388		20000330	
APPLICATION INFO.:	US 2001-787393		20010319	(9)
	WO 1999-JP4128		19990730	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-264367	19980918
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Gitomer, Ralph	

LEGAL REPRESENTATIVE: Fitzpatrick, Cella, Harper & Scinto  
NUMBER OF CLAIMS: 31  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)  
LINE COUNT: 1245

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for the quantitative determination of **cholesterol** in low density lipoproteins and a reagent kit for use therein. The present invention also provides a method for continuous **fractional** determination of **cholesterol** in high density lipoproteins and **cholesterol** in low density lipoproteins and a reagent kit for use therein, as well as a method for continuous **fractional** determination of **cholesterol** in high density lipoproteins and total **cholesterol** and a reagent kit for use therein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2004:209378 USPATFULL  
TITLE: Reagent kit for detecting **cholesterol** in a high-density **lipoprotein**  
INVENTOR(S): Kishi, Koji, Kobe-shi, JAPAN  
Kakuyama, Tsutomu, Kobe-shi, JAPAN  
Ochiai, Koji, Kobe-shi, JAPAN  
Hasegawa, Yuzo, Kobe-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004161811	A1	20040819
APPLICATION INFO.:	US 2004-776970	A1	20040211 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-914552, filed on 30 Aug 2001, PENDING A 371 of International Ser. No. WO 2000-JP1172, filed on 29 Feb 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-53330	19990301
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KILYK & BOWERSOX, P.L.L.C., 53 A EAST LEE STREET, WARRENTON, VA, 20186	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	702	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for quantitating a specific component in lipoproteins contained in a biological sample, for example, HDL (high-density **lipoprotein**), LDL (low-density **lipoprotein**) or VLDL (very low-density **lipoprotein**) by using a commonly employed automatic analyzer without centrifuging or making the reaction liquor cloudy due to complexes or aggregates. Namely, a controlling means, whereby an enzyme reaction can be carried out exclusively for the target component, is introduced into a method for enzymatically assaying a component in a specific **lipoprotein fraction** in the serum, thereby specifically assaying the component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:254332 USPATFULL  
TITLE: Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules  
INVENTOR(S): Hsia, Jen-Chang, Irvine, CA, United States

PATENT ASSIGNEE(S): Synzyme Technologies, Inc., Irvine, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6458758	B1	20021001
APPLICATION INFO.:	US 1997-824739		19970326 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-605531, filed on 22 Feb 1996, now patented, Pat. No. US 5840701 Continuation-in-part of Ser. No. US 1995-482952, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-417132, filed on 31 Mar 1995, now patented, Pat. No. US 5767089 Continuation-in-part of Ser. No. US 1994-291590, filed on 15 Aug 1994, now patented, Pat. No. US 5591710 Continuation-in-part of Ser. No. US 1993-107543, filed on 16 Aug 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1996-US3644	19961003
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Gupta, Anish	
LEGAL REPRESENTATIVE:	Lyon & Lyon LLP	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	71 Drawing Figure(s); 44 Drawing Page(s)	
LINE COUNT:	3590	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and processes to alleviate free radical toxicity are disclosed based on the use of nitroxides in association with physiologically compatible macromolecules. In particular, hemoglobin-based red cell substitutes are described featuring stable nitroxide free radicals for use in cell-free hemoglobin solutions, encapsulated hemoglobin solutions, stabilized hemoglobin solutions, polymerized hemoglobin solutions, conjugated hemoglobin solutions, nitroxide-labelled albumin, and nitroxide-labelled immunoglobulin. Formulations are described herein that interact with free radicals, acting as antioxidant enzyme-mimics, which preserve nitroxides in their active form in vivo. Applications are described including blood substitutes, radioprotective agents, imaging agents, agents to protect against ischemia and reperfusion injury, particularly in cerebral ischemia in stroke, and in vivo enzyme mimics among others.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:22427 USPATFULL  
TITLE: Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules  
INVENTOR(S): Hsia, Jen-Chang, Irvine, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002013263	A1	20020131
APPLICATION INFO.:	US 2001-894237	A1	20010627 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-824739, filed on 26 Mar 1997, PENDING Continuation-in-part of Ser. No. US 1996-605531, filed on 22 Feb 1996, GRANTED, Pat. No. US 5840701 Continuation-in-part of Ser. No. US 1995-482952, filed on 7 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1995-417132, filed on 31 Mar 1995, GRANTED, Pat. No. US 5767089		

Continuation-in-part of Ser. No. US 1994-291590, filed  
on 15 Aug 1994, GRANTED, Pat. No. US 5591710  
Continuation-in-part of Ser. No. US 1993-107543, filed  
on 16 Aug 1993, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1996-US3644	19961003
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LYON & LYON LLP, 633 WEST FIFTH STREET, SUITE 4700, LOS ANGELES, CA, 90071	
NUMBER OF CLAIMS:	46	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	44 Drawing Page(s)	
LINE COUNT:	3767	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and processes to alleviate free radical toxicity are disclosed based on the use of nitroxides in association with physiologically compatible macromolecules. In particular, hemoglo-bin-based red cell substitutes are described featuring stable nitroxide free radicals for use in cell-free hemoglobin solutions, encapsulated hemoglobin solutions, stabilized hemoglobin solutions, polymerized hemoglobin solutions, conjugated hemoglobin solutions, nitroxide-labelled albumin, and nitroxide-labelled immunoglobulin. Formulations are described herein that interact with free radicals, acting as antioxidant enzyme-mimics, which preserve nitroxides in their active form in vivo. Applications are described including blood substitutes, radioprotective agents, imaging agents, agents to protect against ischemia and reperfusion injury, particularly in cerebral ischemia in stroke, and in vivo enzyme mimics among others.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 10 USPATFULL on STN

ACCESSION NUMBER: 1999:81726 USPATFULL  
TITLE: Method for measuring LDL-**cholesterol**  
INVENTOR(S): Miki, Yutaka, Osaka, Japan  
Koyama, Isao, Osaka, Japan  
Imajo, Nobuko, Osaka, Japan  
Futatsugi, Masayuki, Osaka, Japan  
Hanada, Toshiro, Osaka, Japan  
PATENT ASSIGNEE(S): Wako Pure Chemical Industries, Ltd., Osaka, Japan  
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5925534		19990720
APPLICATION INFO.:	US 1998-128930		19980805 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-175396	19980608
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Leary, Louise N.	
LEGAL REPRESENTATIVE:	Armstrong, Westerman, Hattori, McLeland & Naughton	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)	
LINE COUNT:	1561	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The amount of **cholesterol** in low density lipoproteins in a sample can be measured by contacting the sample with one or more reagent solutions to carry out the reaction in the presence of a polyanion and



an amphoteric surfactant, followed by optical measurement of the reaction product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 10 USPATFULL on STN

ACCESSION NUMBER: 1999:36911 USPATFULL

TITLE: Method for measuring an amount of LDL-  
**Cholesterol**

INVENTOR(S): Miki, Yutaka, Amagasaki, Japan  
Imajo, Nobuko, Amagasaki, Japan  
Hanada, Toshiro, Amagasaki, Japan

PATENT ASSIGNEE(S): Wako Pure Chemical Industries, Ltd., Osaka, Japan  
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5885788		19990323
APPLICATION INFO.:	US 1997-897954		19970724 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-214347	19960725
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Leary, Louise N.	
LEGAL REPRESENTATIVE:	Armstrong, Westerman, Hattori, McLeland & Naughton	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 18 Drawing Page(s)	
LINE COUNT:	889	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is to provide a method for measuring an amount of **cholesterol** in low density lipoproteins (LDL-**cholesterol**) in a sample specifically at high accuracy and a reagent used in this method, and the present invention can attain such effect that direct measuring an amount of LDL-**cholesterol** by widely used automatic analyzers can be conducted by using the invention, which has not been possible after known methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 10 USPATFULL on STN

ACCESSION NUMBER: 1998:147418 USPATFULL

TITLE: Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules

INVENTOR(S): Hsia, Jen-Chang, 135 Starcrest, Irvine, CA, United States 92715

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840701		19981124
APPLICATION INFO.:	US 1996-605531		19960222 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-482952, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-417132, filed on 31 Mar 1995 which is a continuation-in-part of Ser. No. US 1994-291590, filed on 15 Aug 1994, now patented, Pat. No. US 5591710 which is a continuation-in-part of Ser. No. US 1993-107543, filed on 16 Aug 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Tsang, Cecilia J.		
ASSISTANT EXAMINER:	Delaney, Patrick R.		
LEGAL REPRESENTATIVE:	Lyon & Lyon LLP		

NUMBER OF CLAIMS: 5  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 70 Drawing Figure(s); 44 Drawing Page(s)  
LINE COUNT: 3768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and processes to alleviate free radical toxicity are disclosed based on the use of nitroxides in association with physiologically compatible macromolecules. In particular, hemoglobin-based red cell substitutes are described featuring stable nitroxide free radicals for use in cell-free hemoglobin solutions, encapsulated hemoglobin solutions, stabilized hemoglobin solutions, polymerized hemoglobin solutions, conjugated hemoglobin solutions, nitroxide-labelled albumin, and nitroxide-labelled immunoglobulin. Formulations are described herein that interact with free radicals, acting as antioxidant enzyme-mimics, which preserve nitroxides in their active form in vivo. Applications are described including blood substitutes, radioprotective agents, imaging agents, agents to protect against ischemia and reperfusion injury, particularly in cerebral ischemia in stroke, and in vivo enzyme mimics among others.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 10 USPATFULL on STN  
ACCESSION NUMBER: 85:33058 USPATFULL  
TITLE: Reagent for the precipitation of apo-B-containing lipoproteins  
INVENTOR(S): Draeger, Brigitte, Tutzing, Germany, Federal Republic of  
Ziegenhorn, Joachim, Starnberg, Germany, Federal Republic of  
PATENT ASSIGNEE(S): Boehringer Mannheim GmbH, Mannheim, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4521519		19850604
APPLICATION INFO.:	US 1982-369382		19820419 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1981-3117455	19810502
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Padgett, Ben R.	
ASSISTANT EXAMINER:	Morkowitz, M.	
LEGAL REPRESENTATIVE:	Felfe & Lynch	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	540	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a reagent for the precipitation of apo-B-containing lipoproteins, wherein it comprises 0.2 to 3 grams per liter of phosphotungstic acid and more than 2 mmols per liter of magnesium ions in aqueous solution.

The present invention also provides a process for the preparation of this reagent and a process for the precipitation of apo-B-containing lipoproteins using this reagent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

=> d his

(FILE 'HOME' ENTERED AT 11:20:24 ON 13 JAN 2006)

FILE 'STNGUIDE' ENTERED AT 11:20:33 ON 13 JAN 2006

FILE 'HOME' ENTERED AT 11:20:38 ON 13 JAN 2006

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODBASE, FEDRIP, ...' ENTERED AT 11:20:43 ON 13 JAN 2006

L1 40 S SUGIUCHI  
L2 17 S L1 AND (CHOLESTEROL OR LIPOPROTEIN)  
L3 16 DUP REM L2 (1 DUPLICATE REMOVED)  
L4 9984 S (CYCLODEXTRAN OR DEXTRAN SULFATE) AND (CHOLESTEROL OR LIPOPRO  
L5 1280 S L4 AND (POLYOXYETHYLENE OR POLYOXYPROPYLENE)  
L6 883 S L5 AND (OXIDASE OR ESTERASE OR DEHYDROGENASE)  
L7 843 S L6 AND (HOMOGENEOUS OR SIMULTANEOUS? OR CONTINUOUS OR SINGL  
L8 820 DUP REM L6 (63 DUPLICATES REMOVED)  
L9 764 S L8 AND FRACTION?  
L10 10 S L9 AND (LIPOPROTEIN OR LDL OR HDL OR LDL-C OR HDL-C OR APOL

=> s l5 and (lipoprotein or ldl or hdl or ldl-c or hdl-c or apolipoprotein or apo-a or apo-b) (a) (fraction)

11 FILES SEARCHED...  
18 FILES SEARCHED...  
21 FILES SEARCHED...  
28 FILES SEARCHED...  
45 FILES SEARCHED...  
54 FILES SEARCHED...  
62 FILES SEARCHED...  
L11 19 L5 AND (LIPOPROTEIN OR LDL OR HDL OR LDL-C OR HDL-C OR APOLIPO  
PROTEIN OR APO-A OR APO-B) (A) (FRACTION)

=>

=> s l11 not l10

49 FILES SEARCHED...  
L12 9 L11 NOT L10

=> dup rem l12

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING COMPLETED FOR L12

L13 2 DUP REM L12 (7 DUPLICATES REMOVED)

=> d l13 1-2 ibib abs

L13 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 1999:30777 USPATFULL

TITLE: Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents

INVENTOR(S): Park, Yong-Bok, Taegu, Korea, Republic of  
Cho, Kyung-Hyun, Taegu, Korea, Republic of

PATENT ASSIGNEE(S): LG Chemical Ltd., Seoul, Korea, Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5880095		19990309
	WO 9615141		19960523
APPLICATION INFO.:	US 1996-666300		19960626 (8)

WO 1995-KR148

19951113

19960626 PCT 371 date

19960626 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	KR 1994-29713	19941112
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Tsang, Cecilia J.	
ASSISTANT EXAMINER:	Celsa, Bennett	
LEGAL REPRESENTATIVE:	Anderson, Kill & Olick, P.C.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	870	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A peptide consisting of the following amino acid sequence, or an analogue or a fragment thereof, has an inhibitory activity on cholesteryl ester transfer protein:

Glu Asp Thr Ser Pro Glu Asp Lys Met Gln Asp Tyr Val Lys Gln Ala Thr Arg  
Thr Ala Gln Asp Ala Leu Thr Ser Val Lys.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 2 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN  
DUPLICATE

ACCESSION NUMBER: 1998:28141347 BIOTECHNO

TITLE: Homogeneous assay for measuring low-density  
**lipoprotein cholesterol** in serum  
with triblock copolymer and  $\alpha$ -cyclodextrin  
sulfate

AUTHOR: Sugiuchi H.; Irie T.; Uji Y.; Ueno T.; Chaen T.;  
Uekama K.; Okabe H.

CORPORATE SOURCE: H. Sugiuchi, Department of Central Laboratory,  
Kumamoto University Hospital, 1-1-1 Honjo, Kumamoto  
860, Japan.

SOURCE: E-mail: sugiuchi@gpo.kumamoto-u.ac.jp  
Clinical Chemistry, (1998), 44/3 (522-531), 27  
reference(s)

CODEN: CLCHAU ISSN: 0009-9147

DOCUMENT TYPE: Journal; Article

COUNTRY: United States

LANGUAGE: English

SUMMARY LANGUAGE: English

AN 1998:28141347 BIOTECHNO

AB We have developed a fully automated method for measuring LDL-  
**cholesterol** (LDL-C) in human serum without the need for prior  
separation, using a nonionic surfactant, **polyoxyethylene-**  
**polyoxypropylene** block copolyether (POE- POP), and a sodium salt  
of sulfated cyclic maltohexaose,  $\alpha$ -cyclodextrin sulfate. Of the  
surfactants tested, POE-POP with a higher molecular mass of the POP block  
and a greater hydrophobicity reduced the reactivity of  
**cholesterol** in **lipoprotein** fractions; the reactivity in  
descending order was LDL >> VLDL > chylomicron .simeq. HDL. Gel  
filtration chromatographic studies revealed that POE-POP removed lipids  
selectively from the **LDL fraction** and allowed them to  
participate in the **cholesterol** esterase-**cholesterol**  
oxidase coupling reaction system. By contrast,  $\alpha$ -cyclodextrin  
sulfate reduced the reactivity of **cholesterol**, especially in  
chylomicrons and VLDL. A combination of POE-POP with  $\alpha$ -cyclodextrin  
sulfate provided the required selectivity for the determination of LDL-C  
in serum in the presence of magnesium ions and a small amount of  
**dextran sulfate** without precipitating

lipoprotein aggregates. There was a good correlation between the results of LDL-C assayed by the proposed method and the beta-quantification reference method involving 161 sera with triglyceride concentrations ranging from 0.3 to 22.6 mmol/L.

=> d his

(FILE 'HOME' ENTERED AT 11:20:24 ON 13 JAN 2006)

FILE 'STNGUIDE' ENTERED AT 11:20:33 ON 13 JAN 2006

FILE 'HOME' ENTERED AT 11:20:38 ON 13 JAN 2006

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIOBASE, FEDRIP, ...' ENTERED AT 11:20:43 ON 13 JAN 2006

L1 40 S SUGIUCHI  
L2 17 S L1 AND (CHOLESTEROL OR LIPOPROTEIN)  
L3 16 DUP REM L2 (1 DUPLICATE REMOVED)  
L4 9984 S (CYCLODEXTRAN OR DEXTRAN SULFATE) AND (CHOLESTEROL OR LIOPRO  
L5 1280 S L4 AND (POLYOXYETHYLENE OR POLYOXYPROPYLENE)  
L6 883 S L5 AND (OXIDASE OR ESTERASE OR DEHYDROGENASE)  
L7 843 S L6 AND (HOMOGENEOUS OR SIMULTANEOUS? OR CONTINUOUS OR SINGL  
L8 820 DUP REM L6 (63 DUPLICATES REMOVED)  
L9 764 S L8 AND FRACTION?  
L10 10 S L9 AND (LIPOPROTEIN OR LDL OR HDL OR LDL-C OR HDL-C OR APOL  
L11 19 S L5 AND (LIPOPROTEIN OR LDL OR HDL OR LDL-C OR HDL-C OR APOL  
L12 9 S L11 NOT L10  
L13 2 DUP REM L12 (7 DUPLICATES REMOVED)

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
537.93	538.41

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.75	-0.75

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:44:21 ON 13 JAN 2006